These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1605286)

  • 41. Clinical experience with ethinyl estradiol and d-norgestrel as an oral contraceptive.
    Apelo R; Veloso I
    Fertil Steril; 1975 Mar; 26(3):283-8. PubMed ID: 1116622
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris.
    Olson WH; Lippman JS; Robisch DM
    Int J Fertil Womens Med; 1998; 43(6):286-90. PubMed ID: 9920537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The androgenicity of oral contraceptives: the young patient's concerns.
    Runnebaum B
    Int J Fertil; 1992; 37 Suppl 4():211-7. PubMed ID: 1362188
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A low-dose combination oral contraceptive. Experience with 1,700 women treated for 22,489 cycles.
    Woutersz TB
    J Reprod Med; 1981 Dec; 26(12):615-20. PubMed ID: 7033528
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mood and physical symptoms improve in women with severe cyclical changes by taking an oral contraceptive containing 250-mcg norgestimate and 35-mcg ethinyl estradiol.
    Nyberg S
    Contraception; 2013 Jun; 87(6):773-81. PubMed ID: 23121822
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick S; Kaye JA; Li L; Jick H
    Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of a triphasic combination oral contraceptive containing norgestimate/ethinyl estradiol on biochemical markers of bone metabolism in young women with osteopenia secondary to hypothalamic amenorrhea.
    Grinspoon SK; Friedman AJ; Miller KK; Lippman J; Olson WH; Warren MP
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3651-6. PubMed ID: 12915650
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of two monophasic oral contraceptives: gestodene/ethinyl estradiol versus desogestrel/ethinyl estradiol.
    Benagiano G
    Int J Fertil; 1989 Sep; 34 Suppl():31-9. PubMed ID: 2576255
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasma lipids and high density lipoproteins during oral contraception with different combinations of ethinyl estradiol and levonorgestrel.
    Larsson-Cohn U; Wallentin L; Zador G
    Horm Metab Res; 1979 Jul; 11(7):437-40. PubMed ID: 225252
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical evidence of the endocrinological influence of a triphasic oral contraceptive containing norgestimate and ethinyl estradiol in treating women with acne vulgaris. A pilot study.
    Sator PG; Schmidt JB; Hönigsmann H
    Dermatology; 2003; 206(3):241-8. PubMed ID: 12673082
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Less estrogen in new oral contraceptive.
    Am J Nurs; 2003 Apr; 103(4):111-2. PubMed ID: 12677126
    [No Abstract]   [Full Text] [Related]  

  • 52. A clinical study of transdermal contraceptive patch in Thai adolescence women.
    Piyasirisilp R; Taneepanichskul S
    J Med Assoc Thai; 2008 Feb; 91(2):137-41. PubMed ID: 18389975
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M; Kitchens CS; Khan FY
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of norgestimate in combination with ethinyl estradiol on cervical mucus.
    Mohsenian M; Moghissi KS; Borin K
    Contraception; 1981 Aug; 24(2):173-81. PubMed ID: 7297068
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative study on the efficacy and acceptability of two contraceptive pills administered by the vaginal route: an international multicenter clinical trial.
    Coutinho EM; de Souza JC; da Silva AR; de Acosta OM; Alvarez F; Brache V; Garza Flores J; Vasquez-Estrada L; Santo R; Bassol S
    Clin Pharmacol Ther; 1993 Jan; 53(1):65-75. PubMed ID: 8422744
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical evidence of the minimal androgenic activity of norgestimate.
    Chapdelaine A; Desmarais JL; Derman RJ
    Int J Fertil; 1989; 34(5):347-52. PubMed ID: 2571595
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen-progestin oral contraceptive. The Mircette Study Group.
    Am J Obstet Gynecol; 1998 Jul; 179(1):S2-8. PubMed ID: 9704812
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial.
    Redmond GP; Olson WH; Lippman JS; Kafrissen ME; Jones TM; Jorizzo JL
    Obstet Gynecol; 1997 Apr; 89(4):615-22. PubMed ID: 9083323
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative trials of low-dose combined oral contraceptives.
    Edelman DA; Kothenbeutel R; Levinski MJ; Kelly SE
    J Reprod Med; 1983 Mar; 28(3):195-200. PubMed ID: 6854550
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A clinical overview of a new triphasic contraceptive containing gestodene.
    Christie T
    Int J Fertil; 1989 Sep; 34 Suppl():40-9. PubMed ID: 2576257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.